Condition: NSCLC (Advanced Non-small Cell Lung Cancer) · HNSCC · CRC (Colorectal Cancer) · Sponsor: ALX Oncology Inc.
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
This description comes directly from the study's public registry record.
Athanasios Tsiatis, MD · 650-466-7125 · info@alxoncology.com
Always discuss trial participation with your own doctor first.
| ALX Center 7 | Tampa, Florida, United States | Recruiting |
| ALX Center 8 | Farmington Hills, Michigan, United States | Recruiting |
| ALX Center 3 | Grand Rapids, Michigan, United States | Recruiting |
| ALX Center 6 | Portland, Oregon, United States | Recruiting |
| ALX Center 5 | Houston, Texas, United States | Recruiting |
| ALX Center 4 | West Valley City, Utah, United States | Recruiting |
| ALX Center 2 | Fairfax, Virginia, United States | Recruiting |
| ALX Center 1 | Spokane, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07085091